rs6809631 — PPARG

Intronic PPARG promoter tagSNP associated with modest reduction in type 2 diabetes risk — co-identified with rs9817428 in the WHI postmenopausal cohort and located within the master regulator of adipogenesis and insulin sensitivity

Emerging Risk Factor Share

Details

Gene: PPARG
Chromosome: 3
Risk allele: A
Clinical: Risk Factor
Evidence: Emerging

Population Frequency

70%

27%

External

SNPedia ClinVar dbSNP

See your personal result for PPARG

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PPARG rs6809631 — A Promoter-Region Marker in the Master Fat-Cell Gene

PPARG (Peroxisome Proliferator-Activated Receptor Gamma¹¹ Peroxisome Proliferator-Activated Receptor Gamma
A nuclear receptor that controls adipocyte differentiation, lipid storage, and insulin sensitivity; the pharmacological target of thiazolidinedione insulin-sensitizing drugs such as pioglitazone and rosiglitazone) is one of the most clinically significant metabolic genes in the human genome. rs6809631 is an intronic variant located within the PPARG promoter region — a stretch of regulatory DNA that controls how much PPARG protein the cell produces. Variants here can subtly tune PPARG expression in adipose tissue and liver without altering the protein sequence itself.

The Mechanism

rs6809631 lies within an intron of PPARG on chromosome 3 (GRCh38 position 12,294,148). Intronic variants in promoter-adjacent regions can influence gene expression through several mechanisms: altering the binding affinity of transcription factor complexes at intronic enhancer elements, modifying RNA splicing²² RNA splicing
The process by which non-coding intron sequences are removed from pre-mRNA before translation — intronic variants near splice sites or branch points can subtly change which exons are included efficiency, or acting as linkage disequilibrium³³ linkage disequilibrium
The tendency of nearby variants to be co-inherited; rs6809631 may mark a functional regulatory variant elsewhere in the PPARG locus that has not been separately catalogued proxies for unidentified functional variants in the same haplotype block.

No molecular mechanism has been published for rs6809631 specifically. Its biological relevance rests on its genomic location within a gene whose regulation is deeply studied and whose activity level determines adipocyte biology at scale: PPARG transcriptionally activates hundreds of target genes controlling fat-cell differentiation, lipid uptake, and fatty acid esterification. Paradoxically, variants that modestly reduce PPARG activity — including the well-characterized Pro12Ala coding variant (rs1801282) — are associated with improved insulin sensitivity, likely because excessive PPARG-driven fat storage in visceral adipose tissue promotes ectopic lipid deposition and systemic insulin resistance. The T allele at rs6809631 may tag similar regulatory variation that reduces PPARG promoter-region activity.

The MAGIC Consortium⁴⁴ MAGIC Consortium
Dimas et al. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes, 2014 classified PPARG alongside IRS1, KLF14, and GCKR as one of four loci whose T2D risk operates primarily through insulin sensitivity rather than insulin secretion — establishing the functional context for all variation at this gene.

The Evidence

The primary evidence for rs6809631 derives from a case-control study nested in the Women's Health Initiative⁵⁵ case-control study nested in the Women's Health Initiative
Chan et al. Common genetic variants in peroxisome proliferator-activated receptor-γ (PPARG) and type 2 diabetes risk among Women's Health Initiative postmenopausal women. J Clin Endocrinol Metab, 2013 involving 1,543 T2D cases and 2,170 matched controls. Twenty-four PPARG tagSNPs were tested by multivariable logistic regression. rs6809631 was among five promoter-region variants significantly associated with reduced T2D risk (odds ratios 0.68–0.78, 95% CIs spanning 0.52–1.00, P ≤ .05). All five variants are in the same PPARG promoter haplotype block; rs9817428 from this group also independently replicated in 5,642 African American and Hispanic American women from the WHI-SHARe cohort (P = .04), strengthening the overall evidence for this haplotype region.

The evidence level for rs6809631 specifically is rated emerging: the OR is reported as a group estimate across five variants rather than per-variant, the cohort is limited to postmenopausal women, and no independent replication has been published for this exact rsid. The PPARG locus-level evidence is substantially stronger and underpins the mechanistic interpretation.

Practical Implications

Because PPARG-region variants act through insulin sensitivity — not through insulin secretion or beta-cell function — the most targeted interventions reduce insulin demand and support adipose tissue health. Omega-3 polyunsaturated fatty acids (EPA and DHA) have been shown to activate PPARγ and upregulate glucose transporters⁶⁶ activate PPARγ and upregulate glucose transporters
González-Périz et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids. FASEB J, 2009 GLUT-2 and GLUT-4, with downstream lipid mediators (resolvins, protectins) producing insulin-sensitizing effects that mirror the thiazolidinedione drug mechanism. Reducing saturated fat amplifies this benefit by reducing competition at the PPARγ ligand binding domain.

Monitoring fasting insulin and HOMA-IR detects insulin resistance before fasting glucose rises into diagnostic ranges — the earliest actionable signal for PPARG-pathway variants. For carriers with T2D or prediabetes requiring pharmacological treatment, pioglitazone directly activates PPARγ; a meta-analysis of 777 patients⁷⁷ meta-analysis of 777 patients
Jang et al. PPARG Pro12Ala Polymorphism and Therapeutic Responses to Thiazolidinediones. Pharmaceutics, 2023 showed PPARG Ala12 carriers achieved 0.3% greater HbA1c and ~11 mg/dL greater fasting glucose reduction on this drug class.

Interactions

rs6809631 is located in the same PPARG gene as the established Pro12Ala missense variant (rs1801282) and two other intronic tagSNPs from the same WHI study: rs9817428 and rs12636454. All three intronic variants operate in the same insulin-sensitivity pathway and may tag overlapping or independent regulatory elements within the PPARG locus. In the broader metabolic context, PPARG variants complement TCF7L2 (rs7903146), which acts through the distinct pathway of incretin signaling and insulin secretion — together these loci represent two major mechanistic axes of type 2 diabetes genetic risk.

Nutrient Interactions

dietary fat altered_metabolism

omega-3 fatty acids altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant:

TT “Protective PPARG Variant” Beneficial

Two copies of the protective T allele — lowest rs6809631-associated T2D risk

You carry two copies of the protective T allele at rs6809631, a genotype found in approximately 3% of people globally. The T allele was among a group of PPARG promoter-region variants associated with reduced type 2 diabetes risk (ORs 0.68–0.78) in the Women's Health Initiative study of 1,543 cases and 2,170 controls. TT homozygosity is most common in East Asian populations (~23%) and rare in African and South Asian populations (<0.1%).

Because the individual OR for rs6809631 alone was not separately reported and evidence derives from a study of postmenopausal women, this protective signal should be interpreted with moderate confidence — but the direction (lower T2D risk with T allele) is consistent with the known biology of PPARG-region variation.

AT “Partial PPARG Protection” Intermediate Caution

One protective T allele and one common A allele — intermediate PPARG-region metabolic risk

You carry one T allele (protective) and one A allele at rs6809631, a genotype found in approximately 27% of people globally. In the Women's Health Initiative study, the T allele was among a group of five PPARG promoter-region variants associated with reduced type 2 diabetes risk (ORs 0.68–0.78, P ≤ .05). As a heterozygous AT carrier you sit between the two homozygous groups.

PPARG operates through insulin sensitivity — this locus primarily influences how effectively your peripheral tissues respond to circulating insulin. The AT genotype is particularly common in East Asian populations (~50%), while fewer than 4% of Africans carry it.

AA “Standard PPARG Risk” High Risk Warning

Two copies of the common A allele — no protective T signal at this PPARG locus

The AA genotype is the most common worldwide, with particularly high frequency in African (~95%) and South Asian (~96%) populations, where the T allele is essentially absent. East Asian populations show the most balanced frequencies (~52% AA), while Europeans are intermediate (~66% AA).

The PPARG promoter region controls transcription of both the PPARγ1 and PPARγ2 isoforms. rs6809631 may tag regulatory variation influencing the ratio or overall level of PPARG expression in adipose tissue, where PPARγ2 is the dominant isoform controlling adipogenesis. If the T allele reduces promoter activity — analogous to the mechanism by which Pro12Ala reduces PPARγ2 transcriptional activity — then AA homozygotes would have the highest PPARG-region expression and potentially the greatest visceral fat storage tendency.

For carriers with T2D or prediabetes, thiazolidinediones (pioglitazone) directly agonize PPARγ — the gene implicated by this variant. The MAGIC consortium data classify PPARG among four insulin-sensitivity loci, distinct from secretion-pathway variants such as TCF7L2.